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ABSTRACT 
Objective: The objectives of this study were to prepare and characterize a buccal mucoadhesive patch using poly (vinyl alcohol) (PVA), poly (vinyl 
pyrrolidone) (PVP) as a mucoadhesive matrix, Eudragit S100 as a backing layer, and lidocaine HCl as a model drug. 
Methods: Lidocaine HCl buccal patches were prepared using double casting technique. Molecular interactions in the polymer matrices were studied 
using attenuated total reflectance-fourier transform infrared spectroscopy (ATR-FTIR), differential scanning calorimetry (DSC) and X-ray 
diffractometry. Mechanical and mucoadhesive properties were measured using texture analyzer. In vitro permeation of lidocaine HCl from the patch 
was conducted using Franz diffusion cell. 
Results: Both of the free and lidocaine HCl patches were smooth and transparent, with good flexibility and strength. ATR-FTIR, DSC and X-ray 
diffractometry studies confirmed the interaction of PVA and PVP. Mechanical properties of matrices containing 60% PVP were significantly lower 
than those containing 20% PVP (*P<0.05). Mucoadhesive properties had a tendency to decrease with the concentration of PVP in the patch. The 
patch containing 60% PVP had significantly lower muco-adhesiveness than those containing 20% PVP (*P<0.05). In vitro permeation revealed that 
the pattern of lidocaine HCl permeation started with an initial fast permeation, followed by a slower permeation rate. The initial permeation fluxes 
follow the zero-order model of which rate was not affected by the PVP concentrations in the PVA/PVP matrix. 
Conclusion: Mucoadhesive buccal patches fabricated with PVA/PVP were successfully prepared. Incorporation of PVP in PVA/PVP matrix affected 
the strength of polymeric matrix and mucoadhesive property of patches. 
Keywords: Poly (vinyl pyrrolidone), Poly (vinyl alcohol), Lidocaine HCl, Permeation, Buccal patch, Buccal drug delivery  




Buccal drug delivery has gained considerable attention as an 
alternative dosage form [1]. Numerous retentive buccoadhesive 
devices [2-6], were developed in order to solve the conventional 
dosage form limitations. Buccal mucoadhesive patches are preferable 
over the buccal tablets for their flexibility, and the patches tend to be 
less obtrusive and are more likely to be accepted by patients. [7]. 
Mucoadhesive patches for buccal mucosa administration may have a 
number of different designs [7, 8]. These patches usually contain 
hydrophilic polymers that are able to form sticky hydrogels after 
getting in contact with water, and adhere to the buccal mucosa and 
the impermeable backing membrane [3]. The impermeable backing 
membrane is an important part to ensure the unidirectional drug 
release [9]. Materials with hydrophobicity, low water permeability 
and drug impermeability properties such as melted wax [10], ethyl 
cellulose [1, 4, 11], and Eudragit RL100 [12] have been used as a 
backing membrane. A wide range of polymers such as 
hydroxypropyl methylcellulose, carbopol, poly (vinyl alcohol) (PVA), 
and poly (vinyl pyrrolidone) (PVP) [13-17] have been employed as a 
matrix and mucoadhesive layer in buccal patches. In order to 
improve the film properties, including film-forming ability, 
mechanical and mucoadhesive properties, a combination of 
hydrophilic polymers is generally used. 
This study will focus on the buccal mucoadhesive bilayered patches 
prepared with PVA and PVP as base matrix polymers. PVA is a well-
known, water-soluble polymer with high transparency and 
flexibility [18]. However, it has a moderate swelling and 
mucoadhesive properties [14, 19]. PVP is a non-ionic, film-forming 
polymer. It has high swelling properties and has been used as 
coadjuvant to increase mucoadhesion [7, 16]. The combination of 
PVA and PVP leads to a more versatile property matrixes. The 
physical, mechanical and thermal properties of PVA and PVP 
matrixes can be modulated by varying the PVA/PVP ratio. These two 
polymers and their blends have been used in numerous applications, 
including biomedical films [20], transdermal [21, 22] and buccal 
patches [13, 14]. Nevertheless, to the best of our knowledge, the 
relationships between PVA/PVP ratios and the mucoadhesion 
property of buccal patches, as well as the permeation behaviour of 
the hydrophilic drug through the mucosa are not well established. 
Lidocaine HCl was used as a hydrophilic model drug. It is very soluble 
in water [23]. It has been reported that lidocaine HCl diffused 
passively through porcine buccal membrane [24]. Lidocaine HCl has a 
primary indication as a local anaesthetic agent when applied topically 
[25, 26]. There are several pharmaceutical dosage forms of lidocaine 
HCl available on the market, i.e., solution for injection or infusion, nasal 
spray, oral gel and transdermal patch [24, 26]. Several authors have 
developed the buccal mucoadhesive systems of lidocaine and/or 
lidocaine HCl [25, 27-29]. However, in previous literature, no attempt 
has been taken to formulate lidocaine HCl buccal patches simply using 
PVA and PVP along with Eudragit S100. 
Being different from the earlier investigations, the objective of this 
study was to prepare a buccal mucoadhesive patch using PVA and PVP 
as a mucoadhesive and drug reservoir layer. Eudragit S100 was used 
as a backing layer. Lidocaine HCl was used as a model drug. The effects 
of PVA/PVP ratios and lidocaine HCl addition on the appearance, 
thickness and mechanical properties of polymer matrices were 
investigated. Molecular interaction, thermal behaviour and solid-state 
characteristics of the drug within the polymer matrices were studied. 
The mucoadhesive properties of buccal patches containing lidocaine 
HCl and the in vitro permeation of lidocaine HCl were also evaluated.  
MATERIALS AND METHODS 
Materials 
Poly (vinyl alcohol) (PVA) was purchased from Ajax Finechem Pty Ltd, 
Seven Hills, Australia. Poly (vinyl pyrrolidone) (PVP) K30 was obtained 
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from K. Science Center and Medical, Khon Kaen, Thailand. Lidocaine HCl 
was purchased from S. Tong Chemicals, Bangkok, Thailand. Dibutyl 
phthalate (DBP) was obtained from Merck-Schuchardt, Hohenbrunn, 
Germany. Methacrylic acid copolymer type B (Eudragit S100) was gifted 
from Evonik Industries AG, Essen, Germany. Deionized water was used 
throughout the studies. All chemicals were of reagent or high-
performance liquid chromatography (HPLC) grade. 
Preparation of blank and lidocaine HCl matrices  
Blank matrices were composed of different concentrations of PVA 
and PVP (table 1) which were prepared by a plate casting method [4, 
15]. PVA was weighted and dissolved in boiled water, while PVP was 
weighted and dissolved in hot water to yield solutions at 12 % w/w. 
The required amount of each solvent was mixed to get the polymer 
solution. The resultant solution was poured into a polypropylene 
plate (12 cm x 12 cm), which was then oven-dried at 55 ○C for 12 h. 
In the case of lidocaine HCl matrices, lidocaine HCl (20% of dry 
weight of polymers) was incorporated into the polymer solution. 
The clear drug-polymer solution was then cast onto the plate and 
subsequently oven-dried as mentioned above. The dry matrices 
were packed in aluminium foil and kept in a desiccator until used. 
Evaluation of blank and lidocaine HCl matrices 
Appearance and thickness  
The appearance and thickness of matrix specimen (rectangular 
shape, 0.5 cm x 4 cm) were observed and measured at five different 
places using a dial thickness gauge (Peacock, Labtek, USA). The 
average of the five values was calculated. 
Molecular interaction  
Attenuated total reflectance-Fourier transform infrared (ATR-
FTIR) spectroscopy 
The spectra (4000 to 650 cm-1 at a resolution of 4 cm-1) of the 
samples were recorded using an ATR-FTIR spectrophotometer 
(Spectrum One, Perkin Elmer, Norwalk, CT). Each sample was cut 
and placed on a ZnSe prism of a sample holder. 
Thermal study 
Differential scanning calorimetry (DSC) curves of the samples were 
recorded using a differential scanning calorimeter (DSC822, Mettler 
Toledo, Switzerland). Each sample (3–5 mg) was accurately weighed 
into a 40-µl open aluminium pan. The measurements were 
performed over 30–300 °C at a heating rate of 10 °C/min. 
X-ray diffractometry 
X-ray diffraction (XRD) measurements of samples were performed 
on an X-ray diffractometer (D8 ADVANCE diffractometer, Bruker, 
Germany). The measurement conditions were Cu radiation 
generated at 40 kV and 40 mA as an X-ray source, angular 5–50 ° 
(2θ), and step angle 0.02 ° (2θ)/s. 
Moisture absorption  
A weighed matrix (1 cm x 1 cm) kept in a desiccator with silica gel 
for 24 h was taken out and transferred to a desiccator containing 
saturated sodium chloride solution (relative humidity 75%) at 25 ○C. 
After equilibrium was attained, the matrix was taken out and 
weighed. Moisture absorption capacity was calculated based on the 
change in the weight with respect to the initial weight of the matrix. 
Mechanical properties  
Mechanical properties which are ultimate tensile strength (UTS), percent 
elongation at break (%E) and Young’s modulus (YM) were determined 
following the method modified from Okhamafe and York [30] using a 
texture analyzer (TA. XT plus, Stable Micro Systems, UK) with a 50-N 
load cell equipped with a miniature tensile grip. The cross-head speed 
was controlled at 10 mm/min. The UTS and percent elongation at break 
were calculated from equations (1) and (2), respectively. 
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Preparation of lidocaine HCl buccal patches 
Lidocaine HCl buccal patches (lidocaine HCl matrices with backing) 
were prepared using double casting technique [3]. An ethanolic 
solution of the backing layer composed of Eudragit S100 and DBP 
(40%) as a plasticizer was poured into a glass plate (diameter = 10 
cm) and subsequently oven-dried at 55 ○C for 2 h. The second matrix 
solution composed of PVA, PVP and lidocaine HCl (table 1) was 
immediately cast on top of the pre-cast dried Eudragit S100 backing 
layer and then oven-dried at 55 ○C for 12 h. The dried patches were 
packed in aluminium foil and kept in a desiccator until used. The patches 
were cut into a size of 20 mm diameter, stored in a desiccator until 
further use. 
Evaluation of lidocaine HCl buccal patches 
Determination of lidocaine HCl content in patches 
A known weight of licocaine HCl matrices was dissolved and diluted 
in water. The licocaine HCl content was determined by an HPLC 
system as described below. 
Determination of mucoadhesive properties of patches 
The mucoadhesive properties of the patches were measured using a 
texture analyzer (TA. XT plus, Stable Micro Systems, UK) with a 50-N 
load cell equipped with a bioadhesive test rig. The patch was 
attached to a 10-mm diameter cylindrical probe using a two-sided 
adhesive tape. The esophageal mucosa of the pig was also obtained 
from a local slaughterhouse (Non-Muang Village, Khon Kaen, 
Thailand). The mucosal membrane from the porcine esophagus 
(about 2 cm × 2 cm) without heat treatment and elimination of the 
connective tissue that had been hydrated with pH 6.8 isotonic 
phosphate buffer (IPB) for 20 min was placed on the stage of 
bioadhesive holder and gently blotted with tissue paper to remove 
excess water on the surface of the mucosal membrane. Next, 100 μl 
of pH 6.8 IPB was pipetted onto the membrane surface before 
testing. The probe and attached patches were moved down at a 
constant speed of 1 mm/s with 0.5-N contact force and 2-min 
contact time. Immediately afterwards, the probe was moved 
upwards with a constant speed of 0.5 mm/s. The relationship 
between the force and patch displacement was plotted. The 
maximum detachment force (Fmax) and work of adhesion (Wad, the 
area under the force versus distance curve) were calculated using 
the Texture Exponent 32 program version 4.0.9.0 (Stable Micro 
Systems). 
In vitro permeation study of lidocaine HCl from patches 
Mucosa preparation 
The porcine oesophagal mucosa was employed in this study because it 
has a lipid composition similar to that of the porcine buccal mucosa, but 
requires a simpler preparation method [31]. The esophageal mucosa 
was obtained from crossbred pigs (hybrid kinds of Duroc Jersey–
Landrace-Large White) that weighed between 80-100 kg and was 
purchased from a local slaughterhouse (Non-Muang Village, Khon Kaen, 
Thailand). The porcine esophageal tube was opened longitudinally and 
immersed in 0.9% sodium chloride at 60 °C for 1 min [31, 32]. The 
epithelium was then peeled away from the connective tissue.  
The in vitro permeation of lidocaine HCl from the patch through the 
porcine esophageal mucosa was conducted using a Franz diffusion cell 
with a diffusion area of 0.636 cm2 (Crown Glass Company, Q1 
Branchburg, NJ). The system was connected to a water bath maintained 
at a temperature of 37.0±0.5 °C. The thickness of a mucosa was 
measured using a dial thickness gauge (Peacock, Labtek, Scotts Valley, 
CA). The mucosa was then mounted on the diffusion cell, which 
contained pH 6.8 IPB as a receptor medium. The lidocaine HCl patch was 
placed over the mucosa and the cell was then fixed and tightly fastened 
with a clamp. At predetermined times, 0.5-ml samples were taken from 
the receptor compartment and equal volumes IPB were immediately 
added after each sampling. The concentration of lidocaine HCl was 
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analyzed by HPLC. The cumulative amount of drug that permeated the 
mucosa was plotted against time. 
Data analysis 
The lidocaine HCl permeation rates from the patches were analyzed 
using both zero-order and Higuchi models [33], which can be 
expressed as equations 3 and 4, respectively, as follows:  
Q = K0t ……. (3) 
and 
Q = KHt1/2 ………… (4) 
Where Q is the amount of lidocaine HCl permeated, t is time, and K0 
and KH are the zero-order and Higuchi permeation rates, 
respectively. 
HPLC analysis 
Lidocaine HCl content was determined using an HPLC system 
(Perkin-Elmer, MA) consisting of a UV/VIS detector (model 785A) 
and a pump (series 200 LC). The chromatographic separation was 
achieved on a Hypersil Gold C-18 column (250 mm × 4.6 mm, 5 μm; 
Thermo Electron Corporation, USA) with a flow rate of 1 ml/min and 
UV detection at 254 nm. The mobile phase consisted of methanol, 
acetic acid, triethylamine and water at a volume ratio of 55: 1.5: 0.5: 
43. The retention time of lidocaine was approximately 4.3 min. The 
standard curve was linear over a concentration range of 5 to 120 
μg/ml with an R2 value>0.99. The day-to-day relative standard 
deviations (RSD) for this assay were less than 5%. 
Statistical analysis 
Each experiment was repeated at least three times. The results are 
expressed as the mean±SD One-way analysis of variance was used to 
test the statistical significance of differences among groups. 
Statistical significance of the differences of the means was 
determined by Student’s t-test. All statistical tests were run using 
the SPSS program for MS Windows, release 19 (SPSS (Thailand) Co. 
Ltd., Bangkok, Thailand). The significance was determined with 95% 
confident limits (α = 0.5) and was considered significant at a level of 
P less than 0.05. 
RESULTS AND DISCUSSION 
Blank and lidocaine HCl matrices  
Both of the blank and lidocaine HCl matrices were prepared by a 
solvent casting method using an aqueous solution of 12% polymer. 
The result shows that the blank matrix made from PVA alone was 
very hard, while the matrix made from PVP alone was very brittle. 
On the contrary, the matrices prepared from PVA and PVP, at all 
concentrations investigated, were flexible, clear with a smooth surface 
and ready to be peeled off from the mould. According to Preis et al. [3], 
the polymer solid content of 10-15% was desirable to yield the matrix 
films with a suitable thickness that could easily be peeled off from the 
release liner. As shown in table 1, the thicknesses of formulations F1, 
F2 and F3 were comparable (P>0.05) and were in the average range of 
125 to 130 µm. The matrix thickness is an important factor affecting 
the strength, flexibility, swelling, drug loading capacity and 
physicochemical stability of the buccal patches [1]. All of the lidocaine 
HCl matrices, formulations LDC-F1, LDC-F2 and LDC-F3, were also 
clear, smooth and uniform, similar to the blank matrices. The 
clearness and transparency of lidocaine HCl matrices suggest that 
lidocaine HCl was solubilized in the polymer matrix. The thicknesses 
of lidocaine HCl matrices were in the average range of 136 to 142 
µm (table 1) which were not different from those of the matrix 
formulations (P>0.05). Therefore, the addition of lidocaine HCl, 20% 
of polymers dry weight, had no effect on the physical appearance of 
the lidocaine HCl matrices. 
  
Table 1: Thickness and mechanical properties of blank and lidocaine HCl matrices as a function of PVA and PVP concentrations 
Formulation Concentration (%) LDC Thickness (µm)a UTS (MPa)a  %E (%)a YM (MPa)a 
PVA PVP 
F1 80 20 - 125±18 59.2±7.0 121.7±54.0 4.6±0.4 
F2 60 40 - 128±27 54.4±6.4 130.2±61.5 4.0±0.5 
F3 40 60 - 130±31 40.4±2.7 40.1±6.0 2.6±0.3 
LDC-F1 80 20 20% 136±14 29.8±2.9 268.8±60.9 2.9±0.3 
LDC-F2 60 40 20% 137±13 19.2±1.4 258.1±48.8 2.1±0.2 
LDC-F3 40 60 20% 142±13 9.0±0.7 261.2±61.1 1.1±0.3 
UTS: ultimate tensile strength, %E: percent elongation at break, YM: Young’s modulus, amean±SD, n = 5. 
 
Molecular interactions 
Molecular interactions between PVA and PVP in the blank and 
lidocaine HCl matrices were investigated using ATR-FTIR 
spectroscopy and XRD analysis. 
ATR-FTIR 
The ATR-FTIR spectra of PVA and PVP powders, PVA/PVP matrix 
(F3), lidocaine HCl matrix containing 60% PVP (LDC-F3) and 
lidocaine HCl powder are shown in fig. 1. In ATR-FTIR spectrum of 
PVA powder (fig. 1a), the wide peak located at 3271 cm-1 is for the 
O-H stretch vibration. Absorption for asymmetrical stretching 
vibration and symmetrical stretching vibration of CH2 occurred at 
2932 and 2908 cm-1, respectively. The two peaks of 1414 and 1326 
cm-1 are attributed to the coupling of the secondary O-H in-plane 
bending and the C-H wagging vibrations. Absorption at 1085 cm-1 
was produced by C-O stretching vibration [34]. The main absorption 
bands of PVP powder were observed at 1661, 1420, 1371 and 1283 
cm-1 (fig. 1b). These bands were assigned as C=O symmetric 
stretching, CH2 bending, O-H bending (in-plane) and C-H 
deformation, respectively [18]. 
The PVA/PVP matrix spectra (fig. 1c, d and e) were similar to those 
of PVA and PVP powders. Nevertheless, the differences between the 
relative ATR-FTIR absorbance of PVA and PVP powders can be seen 
at 3271 cm-1 and in the region of 1800-1500 and 1260-1000 cm-1. 
Blending of PVP with PVA caused the O-H stretching peak of PVA to 
move to higher wavenumbers: 3298-3280 cm-1 and the C-O 
stretching of PVA shifted from 1085 cm-1 to 1091-1089 cm-1. 
Moreover, the C=O stretching of PVP shifted from 1660 cm-1 to 
1655-1651 cm-1. These results indicate the intermolecular 
hydrogen bonding between hydroxyl groups of PVA and carbonyl 
groups of PVP. This result was in agreement with the previous 
report [35]. PVP contains a proton-accepting carbonyl moiety in its 
pyrrolidone ring, whereas hydroxyl groups as side groups are 
presented in the PVA. In PVP/PVA matrices, the hydrogen bonding 
interaction is able to occur between these two moieties [36].  
As shown in fig. 1g, lidocaine HCl powder showed a N-H stretching at 
3383 cm-1, a C-H stretching at 3011 cm-1, an amide I (C=O) at 1654 
cm-1 and an amide II (C-N) at 1472 cm-1. These values are in good 
agreement with the results obtained in other studies [29, 37, 38]. 
Regardless of the PVP content, the ATR-FTIR spectrum of lidocaine 
HCl matrices showed no absence of any functional peak in the 
spectra, revealing that there is no significant chemical interaction 
between the drug and polymers. The example of the spectrum of 
lidocaine HCl matrix prepared with 60% PVP is shown in fig. 1f. 
Additionally, there were no new bands observed in drug-polymer 
matrices, which confirms that no new chemical bonds were formed 
between lidocaine HCl and polymers. 
Limpongsa et al. 




Fig. 1: ATR-FTIR spectra of PVA powder (a), PVP powder (b), PVA/PVP matrices containing 20% PVP (c), 40% PVP (d), 60% PVP (e), 
lidocaine HCl matrix containing 60% PVP (f) and lidocaine HCl powder (g) 
 
Thermal study  
The DSC thermograms of the PVA and PVP powders and PVA/PVP 
matrices are presented in fig. 2. The PVA powder showed an 
endothermic peak at about 213.8 °C (fig. 2a). This was due to the 
melting of the crystalline phase present in this polymer [36]. 
Incorporation of 20 %w/w PVP into the PVA had no effect on the 
DSC pattern as the PVA endothermic peak was at 213.8 °C (fig. 2b). A 
shift of this PVA endothermic peak to lower temperature (205.3 °C) 
was observed for 40% PVP/PVA matrix, and a disappearance of this 
peak occurred at 60% PVP/PVA matrix (fig. 2c-d). However, the 
endothermic peak of their physical mixtures was present at almost 
the same temperature (213.7, 211.0, 213.9 °C for 20, 40 and 60 % 
w/w PVP to PVA, respectively; data not shown). This was 
presumably due to the decreases in the degree of crystallinity and 
crystallization rate of PVA by the PVP [36]. In addition, Seabra and 
De Oliveira [20] reported that the depression in melting 
temperature peak of the crystalline phase of PVA by PVP indicated 




Fig. 2: XRD patterns of PVA powder (a), PVA/PVP matrices containing 20% PVP (b), 40% PVP (c), 60% PVP (d) and PVP powder (e) 
 
The DSC curves of the lidocaine HCl and lidocaine HCl matrices are 
presented in fig. 3. Lidocaine HCl showed an endothermic peak at 
77.9 °C followed by a boiling and volatilization peak starting from 
188 °C (fig. 3a). The endothermic peak of lidocaine HCl was not 
present in the DSC patterns of lidocaine HCl matrices, irrespective 
of PVP concentration in the matrix (fig. 3b-d). This is presumably 
explained by the fact that lidocaine HCl is being solubilized in the 
PVA/PVP matrices. This hypothesis was supported by the DSC 
thermograms of the physical mixture of lidocaine HCl, PVP and 
PVA (data not shown) and other characterization technique shown 
later. 
DSC curves of the lidocaine HCl matrices revealed that incorporation 
of lidocaine HCl (at 20 %w/w of polymer) into the PVA/PVP 
matrices caused a shift of PVA endothermic peak to lower 
temperature at 20% and 40% PVP and disappearance of the 
endothermic peak at 60% PVP (fig. 3b-d). These presumably 
suggested that lidocaine HCl may act as the plasticizer. It is known 
that plasticizers generally affect the thermal and mechanical 
properties of a polymer matrix. Similar findings were observed by 
Aitken-Nichol et al. [39] who found that the glass transition 
temperature of the melting endothermic peak of Eudragit E100 films 
was lower with the addition lidocaine HCl. 
Limpongsa et al. 




Fig. 3: XRD patterns of lidocaine HCl powder (a), lidocaine HCl matrices containing 20% PVP (b), 40% PVP (c), 60% PVP (d) physical 
mixture of lidocaine HCl, 40% PVP-PVA (e) 
 
X-ray diffractrometry 
The XRD patterns of the same materials support the ATR-FTIR and 
DSC results. XRD measurement is a versatile, non-destructive 
technique that reveals the crystallographic structure of materials 
and can be used to investigate the complex formation between the 
polymers. The XRD patterns of PVA and PVP powders and PVA/PVP 
matrices are shown in fig. 4. The XRD pattern of PVA powder 
exhibits diffraction peak angle at 2θ = 10.5 °, 19.8 ° and 41.0 ° (fig. 
4a). The strong and broad peak at 19.8 ° corresponds to the (1 0 1) 
reflection, a plane which contains the extended planar zig-zag chain 
direction of the crystallities [40, 41]. The XRD pattern of PVP 
powder in fig. 4e exhibits amorphous features characterized by two 
halos centered at 2θ = 11.7 ° and 20.2 °. 
For the PVA/PVP matrices, the sharp peak was clearly observed in 
the XRD patterns of the matrices with high PVA content (fig. 4b and 
4c). The intensity of PVA pattern decreased with the addition of PVP. 
This was due to the amorphous nature of the matrix that increased 
with the addition of PVP [35]. The PVA/PVP matrices containing 
60% PVP exhibited the highest amorphous nature as the peak at 2θ 
= 20.0 ° was small and broad (fig. 4d). Based on these findings, it 
could be implied that the degree of crystallization of PVA decreased 
with the increase of PVP content [42]. 
 
 
Fig. 4: DSC thermograms of PVA powder (a), PVA/PVP matrices 
containing 20% PVP (b), 40% PVP (c), 60% PVP (d), and PVP 
powder (e) 
 
Fig. 5 reveals the XRD patterns of lidocaine HCl, lidocaine HCl matrices 
and physical mixture of lidocaine HCl and 40% PVP. Lidocaine HCl was 
highly crystalline in nature as shown by numerous characteristic 
sharp peaks in its XRD pattern. However, the XRD patterns of lidocaine 
HCl matrices (fig. 5b-d) showed one broader peak which were similar 
to those of PVA/PVP matrices (fig. 4b-d). There was no crystalline 
pattern corresponding to that of lidocaine HCl observed. The 
crystallinity nature of lidocaine HCl in lidocaine HCl matrices was 
absent, whereas their physical mixture exhibited a sharp crystalline 
peak (fig. 5e). This suggested that lidocaine HCl embedded in the 
matrix as a solution. In addition, the absence of drug indicated peaks in 
the DSC patterns and matrix physical clarity characteristic. These 
results assured that lidocaine HCl was dispersed with the polymer 
network as a molecular dispersion level. Previous studies showed that 
lidocaine HCl was present in the amorphous condition in a 
hydroxypropyl cellulose film [27] and carbopol film [29]. 
 
 
Fig. 5: DSC thermograms of lidocaine HCl powder (a) and 
lidocaine HCl matrices containing 20% PVP (b), 40% PVP (c) 
and 60% PVP (d) 
 
Moisture absorption 
Moisture absorption study provides information regarding the 
stability of the formulation. Low level of moisture absorption can 
protect the materials from microbial contaminations and bulkiness of 
the polymer matrices [4, 43]. The effects of PVA and PVP 
concentration on moisture absorption of blank matrices were shown 
in fig. 6. The moisture absorption of blank matrices containing PVP at 
20% and 40% were comparable. However, the moisture absorption of 
a matrix containing 60% PVP was significantly higher than that of the 
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one containing 20% PVP (*P<0.05). The relationship between the PVP 
concentration and moisture absorption blank matrices with a high 
coefficient of determination (R2 of 0.9965) was shown. It is obvious 
that the increase of PVP concentration resulted in the increased 
moisture absorption of blank matrices. It is well known that PVA is 
soluble in water while PVP is hygroscopic and freely soluble in water, 
indicating that PVP has more hydrophilicity [44]. The increase of PVP 
content could lead to the higher hydrophilic matrix, leading to the high 
affinity for water and inducing the higher moisture uptake [30]. 
The effects of lidocaine HCl on moisture absorption of lidocaine 
HCl matrices were shown in fig. 6. The moisture absorption of 
matrices increased with lidocaine HCl addition. Significant effects 
of lidocaine HCl addition on the matrix moisture absorption were 
shown, irrespective of the PVP concentration in the matrices 
(*P<0.05). Lidocaine HCl is freely soluble in water [37]. 
Incorporation of lidocaine HCl into the matrix led to an increase in 
the hydrophilic property, which affected the moisture absorption 
of the matrix. 
  
 
Fig. 6: Effect of PVP concentration on moisture absorption of blank and lidocaine HCl matrices (mean±SD, n = 5) 
 
Mechanical properties  
Selection of polymeric matrix as potential buccal mucoadhesive 
system required knowledge of mechanical properties of the matrix. 
Therefore, the mechanical properties of blank matrices prepared 
from various ratios of PVA and PVP were characterized and 
presented in table 1. The ultimate tensile strength (UTS), percent 
elongation at break (%E) and Young’s modulus (YM) of blank 
matrices containing PVP at 20% and 40% were not different. 
However, the UTS, %E and YM of a blank matrix containing 60% PVP 
were significantly lower than those of blank matrices containing PVP 
at 20% and 40% (*P<0.05). 
The relationships between the PVP concentration and UTS and YM 
of blank matrices with a high coefficient of determinations (R2 of 
0.9243 and 0.9478, respectively) are shown in fig. 7. It is obvious 
that the increase of PVP concentration resulted in the decreased UTS 
and YM of blank matrices. Based on the results of ATR-FTIR 
spectroscopy, the hydroxyl groups of PVA and the pyrrolidone rings 
of PVP [36] may have a hydrogen-bonding interaction, resulting in 
the decrease in the inter-molecular forces between polymer chains 
of PVA, leading to the decreases of the UTS and YM. 
The effects of lidocaine HCl on mechanical properties of lidocaine 
HCl matrices were investigated and shown in table 1. The addition of 
lidocaine HCl had effects on the mechanical properties of the 
lidocaine HCl matrix. The UTS and YM of PVA/PVP matrices 
decreased significantly when lidocaine HCl was added to all 
concentrations of lidocaine HCl matrices (*P<0.05). However, the 
percent elongation at break of lidocaine HCl matrices at all ratios 
increased significantly (*P<0.05). From XRD and DSC studies, it was 
confirmed that lidocaine HCl was dissolved as a solution in the 
matrices. Therefore, lidocaine HCl as molecular dispersion, may act 
as a plasticizer which resulted in the increase of %E of the matrix. 
 
 
Fig. 7: Effects of PVP concentration on ultimate tensile strength (UTS) and Young’s modulus (YM) matrices of PVA/PVP (mean±SD, n = 5) 
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Lidocaine HCl patches 
Lidocaine HCl patches (LDC-P1, LDC-P2 and LDC-P3) were 
prepared by laminating one side of formulation LDC-F1, LDC-F2 
and LDC-F3 with a water impermeable backing layer for 
unidirectional drug release. An impermeable backing membrane of 
Eudragit S100 was therefore incorporated into the matrices. 
Eudragit S100 was used as a backing membrane because of its 
hydrophobicity property. Eudragit S100 is an anionic pH-sensitive 
copolymer that can be dissolved at pH 7 [10]. In preliminary 
studies, it was found that the Eudragit S100 films were brittle and 
could not be processed into elastic films. Therefore, DBP was used 
as a plasticizer to reduce the brittleness, impart flexibility, and 
increase toughness, strength, tear resistance, and impact 
resistance of the films. The studies revealed that the addition of 
DBP 40 %w/w of polymer produces smooth, uniform, and flexible 
films. The thicknesses of Eudragit S100 backing layer was 
approximately 28±3 µm. The double-casting protocol employed in 
this study was able to produce the tightly bound, homogeneous 
and smooth surface bilayered patches. The patches of all 
formulation have good flexibility, strength, transparency, and 
smooth surface. The thickness of lidocaine HCl patches ranged 
between 164±15 and 170±15 µm, and mass varied between 
19.4±1.6 and 19.6±1.5 mg/cm2 (data not shown). The thickness 
range was found to be satisfactory which should not cause any 
discomfort to patients when applied [45]. The lidocaine HCl 
content of all formulations was in the average range of 2.53 to 2.57 
mg/cm2 (the percentage labeled amount of 97.4 to 100.0) with a 
low standard deviation (<3%). These results confirmed content 
uniformity of lidocaine HCl in the patches.  
Mucoadhesive properties 
Selection of polymeric matrix as potential buccal system required 
knowledge of mucoadhesive properties of patches. Therefore, the 
mucoadhesive properties in terms of maximum detachment force 
(Fmax) and work of adhesion (Wad) of blank and lidocaine HCl patches 
were characterized using a texture analyzer and presented in fig. 8. 
All blank patches (polymer matrices with backing) showed 
appreciable work of adhesion and maximum detachment force, 
which ranged between 2.7-3.6 N⋅mm and 2.8-3.6 N, respectively. The 
addition of lidocaine HCl had no effect on the mucoadhesive 
properties of the patches compared to those of blank patches. The 
Fmax and Wad of the patches had a tendency to decrease with the 
concentration of PVP in the patch. However, the Fmax and Wad of free 
patches containing PVP at 20% and 40% were comparable. The 
patch containing 60% PVP had significantly lower Fmax and Wad than 
those of patch containing 20% PVP (*P<0.05). In contrast to the 
moisture absorption, the inverted relationship between the PVP 
concentration and the Fmax and Wad of blank patches with a high 
coefficient of determination (R2 of 0.9882 and 0.9981, respectively) 
is shown. However, there is no standard formula available for the 
mucoadhesive buccal drug delivery. This PVA/PVP patch containing 
20 % PVP seems to be appropriate, with a high degree of 
mucoadhesion. 
Mucoadhesion can be defined as the adhesion between a polymer 
and mucus. For the mucoadhesion to occur, an intimate contact 
between polymer and mucus has to take place as a result of a good 
wetting of the matrix surface with saliva [1]. Therefore, the intensity 
of adhesion is closely affected by the moisture absorption of the 
matrices. PVA is a non-ionic polymer that possess mucoadhesive 
properties [46-48] because of numerous hydrogen bond forming 
groups, i.e., hydroxyl groups, contained in its structure. It has been 
proposed that the interaction between the mucus and hydrophilic 
polymers occurs by physical entanglement and chemical 
interactions, such as hydrogen bonding [46]. The interaction of PVA 
with PVP may possibly lower the mobility and flexibility of PVA 
molecules, resulting in a decrease in the physical entanglement of 
PVA and mucus, and bring about a reduction in the number of 
hydroxyl groups of PVA available to interact with the mucus. For 
these reasons, the PVA/PVP patch with a higher concentration of 
PVP displayed a lower mucoadhesive property than that with a 
lower concentration of PVP. These results agree with the study of 
Nafee et al. [13] which reported the decrease in in vitro residence 
time with rabbit intestinal mucosal membrane of PVA patch 
containing miconazole nitrate with PVP concentrations. On the other 
hand, Nappinnai et al. [14] reported that films fabricated with PVA 
and PVP K30 were able to retain the mucosa for a longer period, 
compared to the one prepared with PVA. 
 
 
Fig. 8: Effects of PVP concentration on maximum detachment 
force (a) and work of adhesion (b) of blank patches and 
lidocaine HCl patches (mean±SD, n = 5) 
 
In vitro permeation 
In vitro permeation study is one of the important tools to predict 
how the drug is going to behave in vivo. In the present study, in 
vitro permeation study was performed using porcine esophageal 
mucosa as permeation barrier because it has lipid composition 
which was comparable to that of the porcine buccal mucosa, but 
required a simpler preparation method [31]. The cumulative 
amount of drug permeated per centimetre squared was plotted 
against time as shown in fig. 9. As observed that the pattern of 
lidocaine HCl permeation started with an initial fast permeation 
followed by a slower permeation rate. The steady-state 
permeation fluxes were calculated from the slope of a linear 
portion of the curve using the zero-order and Higuchi models as 
shown in table 2. It was found that the initial permeation rates fit 
well with the zero-order model (equation 1), with R2>0.98. Based 
on the zero-order model, lidocaine HCl permeation rates ranged 
from 8.8±1.3 to 10.2±1.8 µg/cm2/min. Insignificant difference 
between the initial permeation fluxes from lidocaine HCl patches 
prepared with different PVP concentrations was observed 
(P>0.05). It was noted that, irrespective of the PVP concentrations 
in the polymer matrix, the cumulative permeation rates in the first 
120 min of these lidocaine HCl patches were comparable; after 
that, the permeation rates gradually differed. At 240 min, the 
cumulative permeation from LDC-P3 which was prepared with 
60% PVP was significantly lower than that from LDC-P1 which 
was prepared with 20% PVP. These might be attributed to the 
higher hydrophilicity and swelling capacity of the patch prepared 
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with 60% PVP. When the PVA-PVP layer is placed in contact with 
the mucosa, the drug compound migrates through the polymer and 
partitions across the interface of polymer/mucosa, which 
consequently migrates into the mucosa. The initial fast 
permeation may be attributed to the rapid diffusion of the drug 
to the surface of the film [16]. With time, swelling of polymer 
matrix occurred and varied the entanglement of polymeric 
pathways to control the drug diffusion from the matrix. 
Extensive swelling of the PVP contained in LDC-P3 might create 
a thick gel barrier, leading to increasing in mean diffusional path 
length. In addition, similar to transdermal delivery, the 
transmucosal delivery is a phenomenon governing the 
permeation properties and partitioning into the skin of drug and 
the drug release from the polymer matrix. Lidocaine HCl is a 
hydrophilic drug with Log P ≤ 0 [23]. The fact that the latter 
showed slower permeation of drug from LDC-P3 compared to 
that of LDC-P1 patches could also be explained by the higher 
affinity of lidocaine HCl to the hydrated PVP, which lowered the 
tendency of lidocaine HCl to migrate and part into the mucosa. 
 
Fig. 9: Effect of PVP concentration on lidocaine HCl permeation 
from patches across the esophageal mucosal membrane 
(mean±SD, n = 3) 
 
Table 2: Permeation characteristics of lidocaine HCl patches containing difference concentration of PVP 
Formulation Lidocaine HCl permeation rate* Lidocaine HCl permeated at 240 min (µg/cm2) a 
K0 (µg/cm2/min)a KH (µg/cm2/min1/2)a 
LDC-P1 10.2±1.8 (R2 = 0.999) 76.5±15.1 (R2 = 0.945) 1653.9±155.0 
LDC-P2 9.5±2.2 (R2 = 0.981) 71.9±20.0 (R2 = 0.905) 1349.2±96.3 
LDC-P3 8.8±1.3 (R2 = 0.993) 67.3±10.1 (R2 = 0.947) 1044.5±213.8 
*calculated from 0 to 60 min amean±SD, n = 5. 
 
CONCLUSION 
In the present study, mucoadhesive patches fabricated with 
PVA/PVP for buccal delivery of a hydrophilic compound were 
prepared and evaluated. Effects of PVP content in the PVA/PVP 
matrix on the mechanical, mucoadhesive and permeation properties 
were demonstrated. Incorporation of PVP in PVA/PVP matrix caused 
the decrease of crystallization degree of PVA, resulting in the 
decreased strength of polymeric matrix and mucoadhesive property 
of patches. Using lidocaine HCl as a model drug, lidocaine HCl was 
present as a molecular dispersion state in PVA/PVP matrices. The 
dissolved hydrophilic drug affected the mechanical property of 
patch. In vitro permeation results showed the insignificant effect of 
PVA/PVP ratio on the initial permeation fluxes across the mucosa of 
lidocaine HCl from the patches. 
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